Top Medical Companies To Buy For 2014

LONDON -- The shares of Victrex (LSE: VCT  ) advanced 5% to 1,708 pence during early London trade this morning after the specialist plastics developer revealed a marginal improvement in half-yearly profits to 拢35.1 million

Victrex, which produces a virtually unique highly durable plastic called "PEEK", said European sales volumes were 8% ahead of last year.

The company benefited from a 5% improvement in sales of its light-weight PEEK components to the automotive and aviation industries. However, revenues from Victrex's "Invibio" medical division dropped 5% for the period, due to customer destocking in the spinal business.

Victrex confirmed it remains debt free, and by April net cash on the balance sheet had grown 28% to reach 拢74 million.

Chairman Anita Frew commented:�"The Group's strong gross margin has been maintained and we have continued to invest in resources to drive key growth programmes. Cash generation remains strong, funding the PEEK capacity expansion project, which is on track, and underpinning our progressive dividend policy, which is reflected in a 15% increase in the interim dividend."

Hot Growth Companies To Buy Right Now: Biomerieux SA (BIM)

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, such as bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, bioMerieux Benelux SA/NV, among others. In January 2014, it acquired 100% stake in BioFire Diagnostics Inc. Advisors' Opinion:

• [By Jonathan Morgan]

  BioMerieux (BIM) jumped 3.8 percent to 76.53 euros, the largest gain in eight months. The French maker of tests for HIV and hepatitis reported sales for the first half of 754 million euros and confirmed its revenue-growth forecast.

Top Medical Companies To Buy For 2014: Medizone International Inc (MZEI)

Medizone International, Inc. (Medizone), incorporated in January 31, 1986, is a development-stage company. The Company is engaged in research into the medical uses of ozone. Medizone focuses in the field of hospital sterilization. It is a research and development company engaged in developing its AsepticSure. The Company is developing an ozone-based technology (AsepticSure) for decontaminating and sterilizing hospital surgical suites, emergency rooms, and intensive care units.

The Company started hospital beta-testing of a prototype system utilizing the original technology. The first round of in-hospital beta-testing for this AsepticSure hospital disinfection system was completed at a Hotel Dieu hospital in Kingston, Ontario, Canada. In addition to the hospital disinfection system, it employs an ozone-destruct unit which is used following disinfection of the treated infrastructure to reverse the O3 gas in the space, and turn it back into O2 in a short period of time. The Company�� subsidiaries include Medizone Canada, Ltd. (MedCan). As of December 31, 2011, the Company had not generated any revenues.

Advisors' Opinion:

• [By CRWE]

  Today, MZEI surged (+5.64%) up +0.0048 at $.0899 with 21,900 shares in play thus far (ref. google finance Delayed: 1:32PM EDT October 16, 2013).

  Medizone International, Inc. previously reported that its WHO award-winning green infection control technology, AsepticSure has been Granted a patent by the United States Patent and Trademark office. (US 61/223,219) titled “Healthcare Facility Disinfecting System”. The AsepticSure infection control system has repeatedly demonstrated 100% microbial kill rates when used to decontaminate hospital rooms of the causative agents of HAI (hospital acquired infections).

  “With patent protection now established in the United States, Canada and Singapore and pending applications in process for the 37 member countries of the EU as well as Korea, Japan, China, India, Brazil and Mexico, our patent momentum is clearly gaining strength,” stated Edwin Marshall, Medizone’s CEO.

Top Medical Companies To Buy For 2014: TESARO Inc (TSRO)

TESARO, Inc. (TESARO), incorporated in March 2010, is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�� marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells.

Rolapitant

Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). It is in Phase III clinical trials. CINV, if not prevented by prophylaxis, has the potential to afflict up to 90% or more of cancer patients undergoing chemotherapy, depending upon the type of chemotherapy administered the dosing schedule of the chemotherapy, and the patients' age and gender, among other predisposing factors. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization. The Company has in-licensed the rights to rolapitant from OPKO Health, Inc.

TSR-011

TSR-011 is an orally available ALK inhibitor in preclinical development. ALK is known to be involved in certain types of cancers, including subsets of NSCLC, neuroblastoma and lymphoma. For patients in these subsets, the ALK gene is fused to an activating partner or contains point mutations, resulting in constitutive activation of ALK and the growth of cancer cells and tumor development. Inhibition of ALK in these cancer cells results in cell death and tumor growth inhibition or regression. In August 2011, the United States Food and Drug Administration approved the first ALK inhibitor, developed by Pfizer Inc., Xalkori (crizotinib), which was approved for the treatment of patients with locally advanced or metastatic NSCLC that are ALK positive.

The Company competes with GlaxoSmithKline plc, Roche Holding Ltd! . and Sanofi S.A.

Advisors' Opinion:

• [By Ben Levisohn]

  Werber and Eckhard’s favorites include Gilead (GILD) and Celgene (CELG), and they find the “risk/reward…compelling” in Medivation (MDVN) and Tesaro (TSRO).

• [By Brian Orelli]

  Tesaro (NASDAQ: TSRO  ) is also up today after announcing that it established a partnership with clinicians to run the phase 3 development of its PARP inhibitor, niraparib. The trial will enroll about 300 breast cancer patients with BRCA mutations, comparing niraparib to investigators' choice of other breast cancer treatments.

• [By Jake L'Ecuyer]

  Equities Trading UP
  Tesaro (NASDAQ: TSRO) shares shot up 18.28 percent to $28.40 after the company reported successful primary and secondary endpoints in final Phase 3 trial for rolapitant.

Top Medical Companies To Buy For 2014: Waters Corp (WAT)

Waters Corporation (Waters), incorporated on December 6, 1991, is an analytical instrument manufacturer that primarily designs, manufactures, sells and services, through its Waters Division, high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. These systems are complementary products that are frequently employed together (LC-MS) and sold as integrated instrument systems using a common software platform and are used along with other analytical instruments. Through its TA Division (TA), the Company primarily designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments. The Company is also a developer and supplier of software-based products that interface with the Company's instruments and are typically purchased by customers as part of the instrument system. The Company's products are used by pharmaceutical, life science, biochemical, industrial, nutritional safety, environmental, academic and governmental customers working in research and development, quality assurance and other laboratory applications. The Company operates in two segments: Waters Division and TA Division.

In January 2012, the Company acquired Baehr Thermoanalyse GmbH. In July 2012, the Company acquired Blue Reference, Inc. During the year ended December 31, 2012, the Company introduced the Xevo G2-S Q-TofTM and Xevo G2-S Tof mass spectrometers, bringing StepWave ion technology to its bench-top time-of-flight mass spectrometers.

Waters Division

HPLC is used to identify and analyze the constituent components of a variety of chemicals and other materials. HPLC is used to identify new drugs, develop manufacturing methods and assure the potency and purity of new pharmaceuticals. HPLC is also used in a variety of other applica! tions, such as analyses of foods and beverages for nutritional labeling and compliance with safety regulations, the testing of water and air purity within the environmental testing industry, as well as applications in other industries, such as chemical and consumer products. HPLC is also used by universities, research institutions and governmental agencies, such as the United States Food and Drug Administration (FDA) and the United States Environmental Protection Agency (EPA). The ACQUITY UPLC I-Class provides a solution to a critical need by successfully analyzing compounds that are limited in amount or availability.

Waters manufactures LC instruments that are offered in configurations that allow for varying degrees of automation, from component configured systems for academic research applications to fully automated systems for regulated testing, and that have a variety of detection technologies, from ultra-violet (UV) absorbance to MS, optimized for certain analyses. The Company also manufactures tailored LC systems for the analysis of biologics, as well as an LC detector utilizing evaporative light scattering technology to expand the usage of LC to compounds.

The primary consumable products for LC are chromatography columns. These columns are packed with separation media used in the LC testing process and are replaced at regular intervals. The Company's chemistry consumable products also include environmental and nutritional safety testing products. Environmental laboratories use these products for quality control and proficiency testing and also purchase product support services required to help with their federal and state mandated accreditation requirements or with control over critical pharmaceutical analysis. In addition, the Company provides tests to identify and quantify mycotoxins in various agricultural commodities. These test kits provide reliable, quantitative detection of particular mycotoxins through the choice of flurometer, LC-MS or HPLC.

The Co! mpany off! ers a range of MS instrument systems utilizing various combinations of quadrupole, Tof, ion mobility and magnetic sector designs. These instrument systems are used in drug discovery and development, as well as for environmental, clinical and nutritional safety testing. The spectrometers sold by the Company are designed to utilize an LC system as the sample introduction device.

The Company�� smaller-sized mass spectrometers, such as the single quadrupole detector (SQD) and the tandem quadrupole detector (TQD), referred to as LC detectors and are sold as part of an LC system or as an LC system upgrade. Quadrupole systems, such as the Xevo TQ and Xevo TQ-S instruments, are used for late-stage drug development, including clinical trial testing. Quadrupole time-of-flight (Q-Tof) instruments, such as the Company�� SYNAPT G2-S, are used to analyze the role of proteins in disease processes, an application referred to as proteomics. Its SYNAPT G2 HDMS and SYNAPT G2 MS systems are exact mass MS/MS platforms. The Company�� Xevo TQ-S instrument system is designed for UPLC/MS/MS applications. Its Xevo G2 Q-Tof is exact mass quantitative and qualitative bench-top MS/MS instrument systems. The Company�� SYNAPT G2-S incorporates Waters StepWave ion transfer optics and Triwave ion mobility technologies along with a range of informatics tools.

TA Division

Thermal analysis measures the physical characteristics of materials as a function of temperature. Rheometry instruments complement thermal analyzers in characterizing materials. Rheometry characterizes the flow properties of materials and measures their viscosity, elasticity and deformation under different types of loading or other conditions.

Thermal analysis measures the physical characteristics of materials as a function of temperature. Rheometry instruments complement thermal analyzers in characterizing materials. Rheometry characterizes the flow properties of materials and measures their viscosity, elast! icity and! deformation under different types of loading or conditions. As with systems offered through the Waters Division, a range of instrumental configurations is available with sample handling and information processing automation. In addition, systems and accompanying software packages can be tailored for specific applications. The Company�� Q-Series family of differential scanning calorimeters includes a range of instruments, from analyzers to systems, which can accommodate robotic sample handlers and a range of sample cells and temperature control features for analyzing a range of materials.

The Company competes with Agilent Technologies, Inc., Shimadzu Corporation, Bruker Corporation, Danaher Corporation, Thermo Fisher Scientific Inc, PerkinElmer, Inc., Mettler-Toledo International Inc., NETZSCH-Geraetebau GmbH, Thermo Fisher Scientific Inc., Malvern Instruments Ltd., Anton-Paar, Phenomenex, Inc., Supelco, Inc., Merck and Co., Inc. and General Electric Company.

Advisors' Opinion:

• [By Geoff Gannon] strong>Balchem (BCPC)

  路 Idexx (IDXX)

  路 II-VI (IIVI)

  路 Mesa Laboratories (MLAB)

  路 Masimo (MASI)

  I don�� know most of those companies very well. I probably know Waters the best out of that group.

  Obviously, there are companies outside of Phil Fisher�� area of focus ��manufacturing with technical elements ��that fit many of his principles.

  Among really high profile companies, the three that stand out are:

  1. Amazon (AMZN)

  2. Netflix (NFLX)

  3. Wells Fargo (WFC)

  Of those 3, Amazon stands out the most. Jeff Bezos often seems to be channeling Phil Fisher. And I imagine that if Fisher were ever interested in a retailer it would be a retailer with Amazon�� attitude about technology, customers, growth, and the long-term. More than anything though it�� Amazon�� constant internal push to develop new sales and especially new ways to serve existing customers without being prompted by outside forces that makes me think it�� a company Phil Fisher would be very interested in.

  Fisher liked companies that had a philosophy of growth. Something internal to the organization that caused it to seek ways to grow sales, win new customers, develop new products. Fisher obviously wanted a great organization in an industry with great long-term prospects. But I think a lot of growth investors focus more on the latter issue than Fisher would. I know they don�� focus enough on the first issue. Fisher wanted a great organization first and foremost.

  I�� not sure any of the stocks I��e mentioned in this article are necessarily good buys. The one exception is Wells Fargo. I�� never comfortable calling a bank entirely safe. So I�� less sure about suggesting any financial stock as a good buy than I am about stocks in most industries. But if you look at what Wells Fargo has achieved and what they are likely to achieve over the next ten years or so and then consider the price you are paying f

• [By Teresa Rivas]

  Danaher (DHR) and Waters Corporation (WAT) were mirror images of one another, with the former rising 1.3% at recent check and the latter falling by 1.3%.

Top Medical Companies To Buy For 2014: Intelligent Living Inc (ILIV)

Intelligent Living Inc., formerly Feel Golf Co., Inc., incorporated on February 14, 2000, is a developer of healthy aging software tracking systems and wellness centers, which will provide integrated services promoting optimal health and wellness programs. The services to be offered by the Company are personalized programs and regimens developed by nutritionists, fitness specialists and hormone replacement therapists. The Company focuses to offer the benefits of tailored nutritional programs and its products, combined with healthy-aging bio-identical hormone replacement therapies (BHRT). The Company provides services, such as Age Management Medicine, Excercise & Nutrition, MIND360.COM, Nutraceuticals, Hormone Therapy, and Business Solutions.

Age Management Medicine

The Company's Age Management Medicine is a proactive and preventative approach to healthcare for an aging population. The basic tenets of Age Management Medicine include medical history examination of the patient, a thorough lifestyle assessment, and physical and laboratory evaluations, which are used to establish personalized treatment plans.

Business Solutions

The Company is in the development stages of launching its own Electronic Medical Records software. The product will be a Web-based clinical application for the management of patients with hormone and other chronic conditions.

Excercise & Nutrition

The Company has on-site fitness specialists and nutritionists to help one attain goals. Depending on personal goals, personalized consultations are available at their request.

Hormone Therapy

The Company works directly with a pharmacy that compounds products for hormone replacement therapy (HRT). It serves both men and women.

MIND360.COM

Mind360 enhances and maintains people�� mental fitness through an online cognitive training platform. Its engaging brain training games are designed to help strengthen ke! y cognitive functions, including memory, attention, executive functions, thinking and reasoning, and visual perception. Mind360 has over 10,000 users in every continent with more than 40 games.

Nutraceuticals

The Company is focused on optimizing health goals through proper nutrition and dietary supplementation. Its Nutraceutical products support this proactive approach to healthy aging and helps reduce the negative effects of aging and improve quality of life. The Company's Nutraceutical line of products are formulated by both pharmacists and physicians.

Advisors' Opinion:

• [By Peter Graham]

  Small cap healthcare and lifestyle stocks Axxess Pharma Inc (OTCMKTS: AXXE), Medefile International Inc (OTCMKTS: MDFI) and Intelligent Living Inc (OTCMKTS: ILIV) have all been getting some extra attention lately thanks in part to a few disclosed paid promotions or investor relations type of activities. But just how healthy are these small cap stocks for investors and traders alike? Here is a quick reality check:

Top Medical Companies To Buy For 2014: Medifocus Inc (MDFZF)

Medifocus Inc.(Medifocus) is a Canada-based company. The Company is engaged in the business of development and commercialization of minimally invasive, focused-heat tumor targeted cancer treatment devices and systems. Medifocus operates through its wholly owned subsidiary, Celsion (Canada) Limited (Celsion). Celsion had purchased from Celsion Corporation (United States), all of the assets relating to breast cancer Microfocus APA 1000 System (System), consisting of the microwave machine, the adaptive phased array (APA) technology licensed from Massachusetts Institute of Technology (MIT). The Company focuses on breast cancer treatment by using microwave heating to enhance neoadjuvant chemotherapy to provide tumor shrinkage and control. Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks KBridge Energy Corp (OTCMKTS: BMMCF), Medifocus Inc (OTCMKTS: MDFZF) and Inscor Inc (OTCMKTS: IOGA) have been getting some attention lately in various investment newsletters and some of it is deserved as the first stock sank 35% on Friday, the second one recently released its financials (which did show a big improvement, but there is also a big catch for investors) and the third one has been the subject of a very aggressive promotional campaign. But are any of these three small caps really all that hot for investors? Here is a quick reality check: